Midlife sleep characteristics and Alzheimer's disease biomarkers 20 years later
Alzheimer's & Dementia · 2026-04 · 22 (4)
DOI: 10.1002/alz.71342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 14.04.2026. Verfasst von Clémence Cavaillès und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Sleep Wake Disorders, Sleep. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIA NIH HHS, National Heart, Lung, and Blood Institute (NHLBI).
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Poor sleep characteristics are associated with Alzheimer's disease (AD) among older adults; however, this relationship remains underexplored earlier in life. We investigated how early midlife sleep relates to AD‐related biomarkers in late midlife. METHODS A total of 1325 adults (mean age = 40.3 years) self‐reported sleep quality, sleep duration, daytime sleepiness, and insomnia symptoms. Twenty years later, we assessed plasma amyloid beta (Aβ)42/40, tau phosphorylated at threonine 217 (p‐tau217), neurofilament light chain (NfL), and magnetic resonance imaging (MRI)‐derived Spatial Pattern of Abnormality for Recognition of Early AD (SPARE‐AD), characterizing AD‐like brain atrophy. RESULTS After multivariable adjustment, longer sleep duration was associated with lower Aβ42/40, poor sleep quality with higher NfL, daytime sleepiness with both lower Aβ42/40 and higher NfL, and insomnia symptoms with higher SPARE‐AD. No associations were observed with sleep and p‐tau217. DISCUSSION Poor sleep in early midlife was associated with unfavorable AD biomarker levels 20 years later, supporting the idea of sleep as a potential modifiable AD risk factor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, California, USA.
- Centre for Research in Epidemiology and Statistics (CRESS), Epidemiology of Ageing and Neurodegenerative diseases (EpiAgeing), Inserm U1153, INRAE, Université Paris Cité and Université Sorbonne Paris Nord, Paris, France.
- Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Department of Neurology and Center for Circadian and Sleep Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Department of Psychiatry & Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Departments of Neurology, and Epidemiology and Biostatistics, University of California San Francisco and San Francisco VA Medical Center, San Francisco, California, USA.
ORCID-Profile: Clémence Cavaillès
Förderung
- NHLBI NIH HHS
- NIA NIH HHS
- National Heart, Lung, and Blood Institute (NHLBI)
- Coronary Artery Risk Development in Young Adults Study (CARDIA)
- University of Alabama at Birmingham
- Northwestern University
- University of Minnesota
- Kaiser Foundation Research Institute
Zitieren
APA
Cavaillès, C., Carnethon, M. R., Knutson, K. L., Thomas, S. J., & Yaffe, K. (2026). Midlife sleep characteristics and Alzheimer's disease biomarkers 20 years later. Alzheimer's & Dementia, 22(4). https://doi.org/10.1002/alz.71342
Vancouver
Cavaillès C, Carnethon MR, Knutson KL, Thomas SJ, Yaffe K. Midlife sleep characteristics and Alzheimer's disease biomarkers 20 years later. Alzheimer's & Dementia. 2026;22(4). doi:10.1002/alz.71342
BibTeX
@article{Cavaills2026,
author = {Cavaillès, Clémence and Carnethon, Mercedes R and Knutson, Kristen L and Thomas, Stephen Justin and Yaffe, Kristine},
title = {Midlife sleep characteristics and Alzheimer's disease biomarkers 20 years later},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {4},
doi = {10.1002/alz.71342}
}
EUVIMED